Concepedia

Author

Jason G. Harb

The University of Texas MD Anderson Cancer Center

Also Known As

J G Harb, J. Harb, Jason G Harb, Jason G. Harb, Jason Harb

75

Publications

1.9K

Citations

16

H-Index

17

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterAbbVie (United States)Dana-Farber Cancer InstituteThe Ohio State UniversityCancer Genetics (United States)
JG

About

Jason G. Harb is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

628

2

Cell Biology

2

2

579

3

Immunology

1

1

18

4

Pharmacology

1

1

49

5

Cell Signaling

1

1

18

Jason G. Harb

×

20

Publications

1.8K

Citations

16

H-Index

YearCitations

miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts

Anna M. Eiring, Jason G. Harb, Paolo Neviani,

Cell

2010

561

Src homology 2 domain–containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic mice

Stefan Costinean, Sukhinder K. Sandhu, Irene M. Pedersen,

Blood

2009

287

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

Paolo Neviani, Jason G. Harb, Joshua J. Oaks,

Journal of Clinical Investigation

2013

215

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

Christopher J. Walker, Joshua J. Oaks, Ramasamy Santhanam,

Blood

2013

145

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Joshua J. Oaks, Ramasamy Santhanam, Christopher J. Walker,

Blood

2013

108

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Daniel A. Pollyea, Jacqueline S. Garcia,

Blood

2019

71

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

Amer M. Zeidan, Uma Borate, Daniel A. Pollyea,

American Journal of Hematology

2022

70

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia

Houda Alachkar, Ramasamy Santhanam, Jason G. Harb,

Journal of Hematology & Oncology

2013

56

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study

Naveen Pemmaraju, Jacqueline S. Garcia, Jalaja Potluri,

The Lancet Haematology

2022

49

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S. Garcia, Uma Borate,

Blood

2019

44

Page 1